TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19420103

Group type: EXPERIMENTAL
Intervention: Reverse mid-dilution haemodiafiltration (MD-HDF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard mid-dilution haemodiafiltration (MD-HDF)
Number of subjects: 15
Study: 17228349

Group type: EXPERIMENTAL
Intervention: Plant sterol margarine (2 g of plant sterols daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Stanol-enriched margarine (2 g of stanols daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 21
Study: 15342889

Group type: EXPERIMENTAL
Intervention: Behavioral skills training program
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Eddie Eagle GunSafe Program
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: In situ training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Education-based learning materials
Number of subjects: 45
Study: 11718517

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8112538

Group type: EXPERIMENTAL
Intervention: Endoscopic findings of giardiasis duodenitis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal duodenoscopy
Number of subjects: 60
Study: 3003715

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine (RRV) MMU 18006, 10^5 plaque-forming units
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29577919

Group type: EXPERIMENTAL
Intervention: BSA × sPGA
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: BSA
Number of subjects: 3866
Study: 27607861

Group type: EXPERIMENTAL
Intervention: Oxytocin challenge test (5 international units/500 mL oxytocin Ringer lactate infused at a rate of 12 mL/h, doubled every 10 minutes until three uterine contractions per 10‐minute interval)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 78
Study: 26652987

Group type: EXPERIMENTAL
Intervention: 5 mg perindopril arginine salt
Number of subjects: 524

Group type: COMPARATOR
Intervention: 4 mg perindopril tert-butylamine salt
Number of subjects: 524
Study: 23440570

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 689

Group type: COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) 800/200 mg
Number of subjects: 689
Study: 20543746

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) protocol: 15-s intervals at 100% of peak power output (PPO) with 15-s passive recovery intervals.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE) protocol: isocaloric exercise corresponding to 70% of PPO.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both HIIE and MICE protocols.
Number of subjects: 20
Study: 18959704

Group type: EXPERIMENTAL
Intervention: Thermal welding system tonsillectomy (TWS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional 'cold' extracapsular dissection complete tonsillectomy
Number of subjects: 50
Study: 17699280

Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus candesartan (2 to 12 mg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ACE inhibitor
Number of subjects: 90
Study: 14577825

Group type: EXPERIMENTAL
Intervention: Explicit Information (EI) provided to stroke participants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Explicit Information (EI) provided to control participants
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Explicit Information (No-EI) for stroke participants
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Explicit Information (No-EI) for control participants
Number of subjects: 20
Study: 10624998

Group type: COMPARATOR
Intervention: Remifentanil 0 ng/mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Remifentanil 2 ng/mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Remifentanil 4 ng/mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil 8 ng/mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil 16 ng/mL
Number of subjects: 50
Study: 9181203

Group type: EXPERIMENTAL
Intervention: Tobacco purchase attempts by underage confederates at all outlets
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Over-the-counter outlets
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Store factors influencing purchase success
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Smokers purchasing their own tobacco
Number of subjects: 14
Study: 1389512

Group type: EXPERIMENTAL
Intervention: High-dose prochlorperazine 0.8 mg/kg intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose metoclopramide 2 mg/kg intravenously
Number of subjects: 0
Study: 3101865

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg twice daily
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 29398425

Group type: EXPERIMENTAL
Intervention: Didactic group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulation group
Number of subjects: 20
Study: 27383293

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/week IVIG
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg/week IVIG
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 109
Study: 25355723

Group type: EXPERIMENTAL
Intervention: WBRT + TMZ
Number of subjects: 100

Group type: COMPARATOR
Intervention: WBRT
Number of subjects: 100
Study: 23252878

Group type: EXPERIMENTAL
Intervention: 2.5 mg vortioxetine
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: 5 mg vortioxetine
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study: 21335506

Group type: EXPERIMENTAL
Intervention: RCS+AR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Read Naturally (comparison condition)
Number of subjects: 0
Study: 18930603

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 116
Study: 17269614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2950
Study: 15472494

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg (titrated to 10 mg after 4 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg (titrated to 5 mg and 10 mg after 1 and 3 weeks)
Number of subjects: 57
Study: 11751708

Group type: EXPERIMENTAL
Intervention: Fasudil (3.2, 6.4, 12.8, and 25.6 microg/min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.4, 0.8, 1.6, and 3.2 microg/min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resting forearm vascular resistance
Number of subjects: 26
Study: 9443137

Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Graphically supported information
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Video colposcopy
Number of subjects: 147

Group type: COMPARATOR
Intervention: No standardized information (control condition)
Number of subjects: 147
Study: 8420241

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 45
Study: 3526534

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) monotherapy without steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional immunosuppression with azathioprin and prednisone (Aza/P)
Number of subjects: 0
Study: 29415846

Group type: EXPERIMENTAL
Intervention: Opioid-dependence pharmacotherapy (methadone, buprenorphine, oral naltrexone)
Number of subjects: 8736

Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 8736

Group type: EXPERIMENTAL
Intervention: Opioid-dependence pharmacotherapy group
Number of subjects: 8736

Group type: COMPARATOR
Intervention: Outpatient substance abuse treatment without opioid-dependence pharmacotherapy
Number of subjects: 8736
Study: 27569387

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus‐eluting stenting (E‐ZES)
Number of subjects: 8709

Group type: COMPARATOR
Intervention: Cypher sirolimus‐eluting stenting (C‐SES)
Number of subjects: 8709
Study: 24571282

Group type: EXPERIMENTAL
Intervention: Daily text messages for 6 months
Number of subjects: 659

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 659
Study: 22087047

Group type: EXPERIMENTAL
Intervention: Take Charge Session
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: DVD of four inspirational stories
Number of subjects: 172
Study: 21110437

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 250-1000 mg ademetionine for 28 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Yinzhihuang Granule and Compound Glycyrrhizin Injection (control group)
Number of subjects: 33
Study: 17237966

Group type: EXPERIMENTAL
Intervention: Extended Matching (EM) question format
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Short Answer (SA) question format
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypothetico-deductive reasoning
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Straightforward task
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Difficult task
Number of subjects: 13
Study: 15918812

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 382
Study: 12814852

Group type: EXPERIMENTAL
Intervention: venlafaxine XR (75 or 150 mg/d)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: diazepam (15 mg/d)
Number of subjects: 540

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: venlafaxine XR (75 or 150 mg/d) from verum-sensitive centres
Number of subjects: 540
Study: 10480771

Group type: EXPERIMENTAL
Intervention: Severe personal stressors (SPS) reported in the month before HbA1c measurement
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Positive life events reported during the same time period
Number of subjects: 55
Study: 8933997

Group type: EXPERIMENTAL
Intervention: Methoxamine (vasoconstrictor)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Strain gauge method
Number of subjects: 6

Group type: COMPARATOR
Intervention: Finapres (finger arterial blood pressure monitor)
Number of subjects: 6
Study: 1653140

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan (second dose at 1 hour)
Number of subjects: 235

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 235

Group type: COMPARATOR
Intervention: placebo (second dose at 1 hour)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: sumatriptan
Number of subjects: 235

Group type: COMPARATOR
Intervention: sumatriptan and placebo
Number of subjects: 235
Study: 6411497

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 25 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 50 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mesterolone (100 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Testosterone rebound therapy (100 or 250 mg on alternate weeks)
Number of subjects: 46
Study: 29781580

Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Volitional Resistance Training
Number of subjects: 59
Study: 28877115

Group type: EXPERIMENTAL
Intervention: Moisturizer C (high levels of glycerin)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moisturizer E (high levels of glycerin)
Number of subjects: 25
Study: 27240397

Group type: EXPERIMENTAL
Intervention: Acute cocoa consumption
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Regular cocoa consumption
Number of subjects: 33
Study: 25092937

Group type: EXPERIMENTAL
Intervention: In situ simulation training (4-hour session for multidisciplinary groups of 6 professionals)
Number of subjects: 120
Study: 22687173

Group type: EXPERIMENTAL
Intervention: Implementation intention (if-then plan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation intention (focused on odds of winning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no implementation intention)
Number of subjects: 0
Study: 19627686

Group type: EXPERIMENTAL
Intervention: New therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised clinical trials
Number of subjects: 0
Study: 16904451

Group type: EXPERIMENTAL
Intervention: Prostate volume estimated by DRE
Number of subjects: 35323

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 35323

Group type: EXPERIMENTAL
Intervention: Prostate volume increase (10 cm3)
Number of subjects: 35323

Group type: EXPERIMENTAL
Intervention: Correlation of log PSA and prostate volume
Number of subjects: 35323

Group type: EXPERIMENTAL
Intervention: Prostate volume
Number of subjects: 35323
Study: 15534554

Group type: EXPERIMENTAL
Intervention: Wide cuff
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cuff
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Automated limb occlusion pressure technique and wide contoured cuff
Number of subjects: 40
Study: 11730651

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9386141

Group type: EXPERIMENTAL
Intervention: Maxepa 5 capsules BID for 3 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 16
Study: 7910181

Group type: EXPERIMENTAL
Intervention: Whole body disinfection
Number of subjects: 3466

Group type: EXPERIMENTAL
Intervention: Careful post-discharge follow-up
Number of subjects: 3466

Group type: COMPARATOR
Intervention: Clean operations
Number of subjects: 3466

Group type: COMPARATOR
Intervention: Potentially contaminated procedures
Number of subjects: 3466

Group type: COMPARATOR
Intervention: Horizontal wounds
Number of subjects: 3466

Group type: COMPARATOR
Intervention: Vertical wounds
Number of subjects: 3466

Group type: COMPARATOR
Intervention: Use of drains
Number of subjects: 3466
Study: 3219274

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg bd
Number of subjects: 220

Group type: COMPARATOR
Intervention: Primary endocrine treatment alone (PET)
Number of subjects: 220
Study: 30772906

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28259552

Group type: EXPERIMENTAL
Intervention: Learning and Coping Strategies (LC) plus Cardiac Rehabilitation (CR)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Cardiac Rehabilitation (CR) alone
Number of subjects: 825
Study: 26666321

Group type: EXPERIMENTAL
Intervention: Information booklet plus one additional pre-operative physiotherapy education and training session
Number of subjects: 441

Group type: COMPARATOR
Intervention: Information booklet
Number of subjects: 441
Study: 23234810

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 20 mg/d (early-treatment)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo (delayed-treatment)
Number of subjects: 409
Study: 21218293

Group type: EXPERIMENTAL
Intervention: Negatively framed education about CPAP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Positively framed education about CPAP
Number of subjects: 70
Study: 18419877

Group type: EXPERIMENTAL
Intervention: budesonide DPI‐A 200 microg x 4 inhalations
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: budesonide DPI‐B 180 microg x 4 inhalations
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: budesonide DPI‐B 90 microg x 8 inhalations
Number of subjects: 37
Study: 15333721

Group type: EXPERIMENTAL
Intervention: DHA-enriched baby food (115 mg DHA/100 g food, 1 jar (113 g)/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control baby food (0 mg DHA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DHA-enriched baby food
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control baby food
Number of subjects: 51
Study: 12236335

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 43

Group type: COMPARATOR
Intervention: No monetary incentive (control)
Number of subjects: 43
Study: 11907915

Group type: EXPERIMENTAL
Intervention: Soy diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Linseed diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wheat diet
Number of subjects: 100
Study: 8083711

Group type: EXPERIMENTAL
Intervention: Split hyperfractionated radiotherapy (2.0 Gy/d for 30 to 40 days, total 48 Gy to 60 Gy) and chemotherapy (cisplatin 80 to 100 mg/m2 and fluorouracil 1,000 mg/m2 for 3 to 4 days, +/- vindesine 8 mg/m2 for two cycles)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Split hyperfractionated radiotherapy and chemotherapy
Number of subjects: 91
Study: 2809258

Group type: EXPERIMENTAL
Intervention: Purified acellular pertussis vaccine (12.5 micrograms LPF and 12.5 micrograms FHA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional pertussis vaccine
Number of subjects: 130
Study: 1108565

Group type: EXPERIMENTAL
Intervention: Heparin 5,000 i.u. every 12 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31799870

Group type: EXPERIMENTAL
Intervention: Histogram-based features
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Histogram-based features and texture-based features
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Histogram-based features and Laws features
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Histogram-based features, texture-based features, and Laws features
Number of subjects: 115
Study: 31661012

Group type: EXPERIMENTAL
Intervention: Biological dressing composed of fetal fibroblasts and keratinocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional dressing
Number of subjects: 0
Study: 27610591

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 29

Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 29
Study: 25982826

Group type: EXPERIMENTAL
Intervention: Brain Fitness
Number of subjects: 27

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 27
Study: 24206740

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus acidophilus)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 22123381

Group type: EXPERIMENTAL
Intervention: Levocetirizine, 5 mg daily for 1 week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg daily for 1 week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pill for 1 week
Number of subjects: 30
Study: 19329820

Group type: EXPERIMENTAL
Intervention: CABG with surgical ventricular reconstruction
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 1000
Study: 16691131

Group type: EXPERIMENTAL
Intervention: ICP-directed therapy in patients with severe TBI (n = 24)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PILOT scale scores for severe TBI patients (group 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: PILOT scale scores for mild-moderate TBI patients (group 2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: PILOT scale scores for extracranial trauma patients (group 3)
Number of subjects: 27

Group type: COMPARATOR
Intervention: PILOT scale scores for nontraumatic illness patients (group 4)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of PILOT scale scores with Glasgow Coma Scale
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of PILOT scale scores with overall Injury Severity Score
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of PILOT scale scores with head component of Injury Severity Score
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of PILOT scale scores with 6-month Glasgow Outcome Scale
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of PILOT scale scores with ICP burden
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of PILOT scale scores with mean ICP
Number of subjects: 27
Study: 15285121

Group type: EXPERIMENTAL
Intervention: Different descriptions of winning conditions (e.g., 'if one or the other but not both picks a red card' vs. 'if one or the other but not both picks a black card')
Number of subjects: 0
Study: 11399700

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 9421821

Group type: EXPERIMENTAL
Intervention: Simulated pursed lips breathing (SPLB) with positive expiratory pressure of 5 cm H2O
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simulated pursed lips breathing (SPLB)
Number of subjects: 12
Study: 8276048

Group type: EXPERIMENTAL
Intervention: Ramipril 1.25 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3440636

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of ketanserin and hydrochlorothiazide
Number of subjects: 20
Study: 30355094

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 214
Study: 29444393

Group type: EXPERIMENTAL
Intervention: 6% inspired sevoflurane in 50% O₂/N₂0, no manually assisted ventilation
Number of subjects: 20

Group type: COMPARATOR
Intervention: 8% inspired sevoflurane in 50% O₂/N₂0, manually supported ventilation upon loss of consciousness
Number of subjects: 20
Study: 25064437

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 120/180/240 μg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (alfa) 180 μg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 180 μg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 240 μg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (alfa)
Number of subjects: 392